Welcome to our dedicated page for PETVIVO HOLDINGS WTS news (Ticker: PETVW), a resource for investors and traders seeking the latest updates and insights on PETVIVO HOLDINGS WTS stock.
PETVIVO HOLDINGS INC WTS (symbol: PETVW) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. With a strategic approach of leveraging investments in human biomaterials and medical device industries, PETVIVO aims to bring therapeutics to pets in a capital and time-efficient manner. The company's core strategy involves in-licensing proprietary products from human medical device companies for pet use. PETVIVO HOLDINGS INC WTS is the parent company of petvivo, inc, gel-del technologies, inc, and cosmetalife corporation.
Rhea-AI Summary
PetVivo Holdings, Inc. announces the issuance of a notice of allowance for a patent application by the United States Patent and Trademark Office (USPTO) related to the Company’s proprietary biomaterials and corresponding products. The patent provides protection for a broad range of proprietary products, including the biocompatible sponge-like particles used in PetVivo’s signature product, Spryng™ with OsteoCushion™ Technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
PetVivo Holdings, an emerging biomedical device company (NASDAQ: PETV & PETVW), will exhibit its lead product, Spryng with OsteoCushion Technology, at the Veterinary Meeting & Expo Conference from January 14th to 17th, 2024. The intra-articular injectable veterinary medical device is designed to manage joint-related afflictions such as osteoarthritis, and the company aims to network with industry leaders at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has entered into a definitive distribution agreement with Covetrus North America, LLC to market and promote its veterinary medical device, Spryng™ with OsteoCushion™ technology, throughout the United States. Covetrus sales and marketing activities will commence on January 1, 2024. This strategic partnership aims to benefit the veterinary industry, the veterinarians, the animals receiving Spryng, and the owners benefiting from the enhanced medical outcomes of their animals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
News
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) achieved a significant milestone by distributing over 4500 syringes of Spryng™ with OsteoCushion™ technology to veterinarians in 2023. This represents a 60% increase from the previous year. The positive outcomes experienced by animals injected with Spryng have driven its momentum, with high enthusiasm from veterinarians and upcoming clinical studies and trade show exposure expected to further boost distribution in the new year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV & PETVW) achieves a significant milestone by selling its signature product Spryng™ with OsteoCushion™ Technology to over 600 veterinary clinics in 49 states.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (PETV, PETVW) will be showcasing its lead product, SPRYNG™ with OsteoCushion™ Technology at the American Association Equine Practitioners conference, aiming to network with industry professionals and drive forward its innovative veterinary medical device. The conference will be held from November 29th to December 2nd, 2023 at the San Diego Convention Center in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. (Nasdaq: PETV) announces financial results for the three months ended September 30, 2023. Key highlights include the release of clinical study results for Spryng™, raising $2.35 million from stock offerings, and entering into an ATM Sales Agreement with ThinkEquity, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. (NASDAQ: PETV and PETVW) will report financial results on November 14, 2023, after market close. The company will host a conference call to discuss these results at 4:00 p.m. CT (5:00 p.m. ET) on the same day. Attendees can register and access the webcast on PetVivo’s Investor Relations website. A replay of the webcast will be available through the same link. Participants can also access the call using the provided dial-in details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PetVivo Holdings, Inc. announced that two members of its Scientific/Veterinarian Team will present at the AAEP annual convention. Tom Yarbrough will discuss new classes of joint therapeutics, while Joseph Manning will talk about a novel collagen-elastin hydrogel microparticles biomaterial for joint conditions in equines. The presentations will take place from November 30th to December 2nd, 2023 in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
PetVivo Holdings, Inc. received positive response for its innovative product Spryng™ with OsteoCushion™ technology at the ACVS conference. Two presentations and a clinical study demonstrated the benefits and tolerability of Spryng™ in managing joint-related afflictions in companion animals. The study showed significant improvements in pain, lameness, and quality of life scoring. Spryng™ is a non-invasive alternative for patients with cranial cruciate disease when surgery is not an option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
FAQ
What is the current stock price of PETVIVO HOLDINGS WTS (PETVW)?
The current stock price of PETVIVO HOLDINGS WTS (PETVW) is $0.0295 as of December 24, 2024.
What does PETVIVO HOLDINGS INC WTS specialize in?
PETVIVO focuses on licensing and commercializing innovative medical devices for pets, also known as pet therapeutics.
What is PETVIVO's strategic approach?
The company leverages investments in human biomaterials and medical device industries to efficiently bring therapeutics to pets.
How does PETVIVO commercialize products for pets?
PETVIVO in-licenses proprietary products from human medical device companies specifically for pet use.
What subsidiaries are under PETVIVO HOLDINGS INC?
petvivo, inc, gel-del technologies, inc, and cosmetalife are all wholly-owned subsidiaries of PETVIVO HOLDINGS INC.
What is PETVIVO's core business model?
PETVIVO's core model involves commercializing innovative medical devices for pets through strategic partnerships.
What is the significance of PETVIVO in the biomedical device industry?
PETVIVO plays a crucial role by bringing human medical advancements to the pet therapeutics sector.
How does PETVIVO ensure efficient commercialization of pet therapeutics?
PETVIVO's strategy focuses on in-licensing products from human medical device companies, streamlining the process.
What sets PETVIVO apart in the pet therapeutics market?
PETVIVO's unique approach of leveraging human medical device technology for pets sets it apart in the industry.
What are some recent achievements of PETVIVO HOLDINGS INC WTS?
PETVIVO has successfully partnered with leading human medical device companies to bring cutting-edge therapeutics to pets.
What can investors expect from PETVIVO's future projects?
Investors can anticipate further advancements in pet therapeutics through PETVIVO's ongoing projects and collaborations.
PETVIVO HOLDINGS INC WTS